Evidence map›Paper›PMID 41778251›Full record

ArticleCancer diagnosis & prognosis

Development of Second Primary Malignancies in Long-term Survivors of Unresectable Esophageal Cancer.

Ryotaro Watanabe, Seiichiro Mitani, Masaki Okura, Chiaki Inagaki, Junko Tanizaki, Kaoru Tanaka, Tsutomu Iwasa, Kimio Yonesaka, Hidetoshi Hayashi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ryotaro WatanabeDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Sakai, Japan.
Seiichiro MitaniDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Sakai, Japan.
Masaki OkuraDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Sakai, Japan.
Chiaki InagakiDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Sakai, Japan.
Junko TanizakiDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Sakai, Japan.
Kaoru TanakaDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Sakai, Japan.
Tsutomu IwasaDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Sakai, Japan.
Kimio YonesakaDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Sakai, Japan.
Hidetoshi HayashiDepartment of Medical Oncology, Faculty of Medicine, Kindai University, Sakai, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: The recent advent of immunotherapy has improved long-term survival in patients with unresectable esophageal cancer. However, second primary malignancies (SPMs) are expected to develop in these patients. We investigated the incidence of SPMs in patients with unresectable advanced esophageal cancer. Patients and Methods: We retrospectively reviewed the records of patients with unresectable esophageal cancer, including those with locally advanced and metastatic disease, who were treated at the Kindai University Hospital between 2016 and 2022. The incidence of SPMs was determined among long-term survivors. The cumulative incidence of SPMs was estimated using the Gray subdistribution method, treating death as a competing risk. Results: Among the 211 patients with unresectable esophageal cancer, 45 (21%) met the criteria for long-term survival. Five (11%) were diagnosed with SPMs after a median follow-up of 3.7 years. The cumulative incidences of SPMs after 3, 5, and 8 years were 7, 10, and 14%, respectively. The types of SPMs included diffuse large B-cell lymphoma and urothelial, lung, prostate, and thyroid cancers. All SPMs were cured with definitive treatment, and no deaths were attributed to them. Conclusion: Even among patients with unresectable esophageal cancer

Indexed as

Esophageal cancerimmune checkpoint inhibitorslong-term survivorsecond primary malignancy

Identifiers

PMID41778251
PMCPMC12951366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.